Patent Expiry

Patent/Exclusivity Expiry: YUPELRI

Other upcoming events for TBPH

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: YUPELRI — TBPH Patent Expiry | BioSniper